Kenvue Goes Boom - Now What?
Johnson & Johnson spun off its consumer segment into Kenvue, a $40 billion company in the consumer defensive sector. Kenvue operates in three main segments, including well-known brands like Tylenol, Neutrogena, and Listerine, with a global sales distribution. Despite recent underperformance, Kenvue saw a 14% stock price rally after reporting 2Q24 earnings, beating market expectations and showing signs of optimism.
S&P 500 Gains and Losses Today: Kenvue Soars on Band-Aid Maker's Strong Outlook
Major U.S. equities indexes rebounded on Tuesday following three turbulent days of trading that saw heightened levels of economic uncertainty send stocks tumbling.
Kenvue Inc. (KVUE) Q2 2024 Earnings Call Transcript
Kenvue Inc. (NYSE:KVUE ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Jim Giannakouros - Interim Head, Investor Relations Thibaut Mongon - Chief Executive Officer Paul Ruh - Chief Financial Officer Conference Call Participants Anna Lizzul - BofA Securities, Inc. Steve Powers - Deutsche Bank Securities, Inc. Andrea Teixeira - JPMorgan Securities LLC Nik Modi - RBC Capital Markets LLC Filippo Falorni - Citigroup Global Markets, Inc. Susan Anderson - Canaccord Genuity Jeremy Fialko - HSBC Peter Grom - UBS Operator Hello and welcome to the Kenvue Second Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.
Band-Aid, Tylenol Parent Kenvue Reports Healthy Full-Year Guidance
Kenvue (KVUE) shares surged in intraday trading Tuesday after the company affirmed its full-year guidance that topped analysts' expectations.
Kenvue News: Why Investors Are Loving KVUE Stock This Week
Among the key stocks in focus in today's session is Kenvue (NYSE: KVUE ). The company, which was spun off from parent Johnson & Johnson (NYSE: JNJ ) almost exactly one year ago, is seeing strong traction in the market today.
Kenvue Is the S&P 500 Stock After Earnings. Here's Why.
Shares of the Band-Aid parent are on track for their largest daily percent increase on record.
Compared to Estimates, Kenvue (KVUE) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Kenvue (KVUE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Kenvue (KVUE) Q2 Earnings and Revenues Beat Estimates
Kenvue (KVUE) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.32 per share a year ago.
Kenvue stock up 9% after earnings beat; consumer health stars
Shares in Kenvue Inc (NYSE:KVUE) were up 9% in pre-market trading after the company exceeded Wall Street's expectations for second-quarter profit and revenue. The consumer health company, spun off from Johnson & Johnson (NYSE:JNJ) last year, reported strong sales in its essential health products unit, which includes Tylenol, Listerine, and Neutrogena.
Kenvue's stock jumps as Band-Aid, Tylenol parent beat profit and sales expectations
Shares of Kenvue Inc. KVUE, -3.35% jumped 3.4% in premarket trading Tuesday, after the parent of consumer health brands including Band-Aid, Tylenol and Listerine reported second-quarter earnings that beat expectations, boosted by productivity gains and higher pricing. Net income fell to $58 million, or 3 cents a share, from $430 million, or 23 cents a share, in the year-ago period.
Listerine maker Kenvue beats estimates on strong essential health product sales
Kenvue beat Wall Street estimates for second-quarter profit and revenue on Tuesday, helped primarily by better-than-expected sales in its essential health products unit that sells brands including Band-Aid, Listerine and Carefree.
Is Kenvue The Next Big Dividend (Growth) Stock?
Kenvue stock has not participated in the recent rotation into value stocks. It trades at a forward P/E of 16 and a free cash flow yield of 6%. Such a valuation is indeed rare to find in the - typically overvalued - consumer staples sector, as is a starting dividend yield of 4.4%. In this article, I explain the main reasons for my growing enthusiasm and why I expect to initiate a long position in KVUE stock shortly.
